The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
The Clinically Important Difference on the Unified Parkinson's Disease Rating Scale
Abstract
Objective To determine the estimates of minimal, moderate, and large clinically important differences (CIDs) for the Unified Parkinson's Disease Rating Scale (UPDRS). Design Cross-sectional analysis of the CIDs for UPDRS total and motor scores was performed on patients with Parkinson disease (PD) using distribution- and anchor-based approaches based on the following 3 external standards: disability (10% on the Schwab and England Activities of Daily Living Scale), disease stage (1 stage on the Hoehn and Yahr Scale), and quality of life (1 SD on the 12-Item Short Form Health Survey). Setting University of Maryland Parkinson Disease and Movement Disorders Center, Patients Six hundred fifty-three patients with PD. Results A minimal CID was 2.3 to 2.7 points on the UPDRS motor score and 4.1 to 4.5 on the UPDRS total score. A moderate CID was 4.5 to 6.7 points on the UPDRS motor score and 8.5 to 10.3 on the UPDRS total score. A large CID was 10.7 to 10.8 points on the UPDRS motor score and 16.4 to 17.8 on the UPDRS total score. Conclusions Concordance among multiple approaches of analysis based on subjective and objective data show that reasonable estimates for the CID on the UPDRS motor score are 2.5 points for minimal, 5.2 for moderate, and 10.8 for large CIDs. Estimates for the UPDRS total score are 4.3 points for minimal, 9.1 for moderate, and 17.1 for large CIDs. These estimates will assist in determining clinically meaningful changes in PD progression and response to therapeu…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The observed mean changes in MDS-UPDRS Part III OFF (8.6 low-dose, 23 high-dose) are consistent with a moderate and large clinically important difference in motor scores, respectively.
“Our data show a mean change of 8.6 points in the low-dose cohort and 23 points in the high-dose cohort, consistent with a moderate and large ‘clinically important difference’ in motor scores41, respectively.”
From Phase I trial of hES cell-derived dopaminergic neurons for Parkinson’s disease (2025) · cites this paper as [41]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
WARE, J. E., KOSINSKI, M., & KELLER, S. D. (1996) · Medical Care · doi:10.1097/00005650-199603000-00003 · Cited by 17,392
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2003) · Medical Care · doi:10.1097/01.mlr.0000062554.74615.4c · Cited by 4,700
Flagged first, then by citations
Cited by
Sorted by citations
LeWitt, P. A., Rezai, A. R., Leehey, M. A., Ojemann, S. G., Flaherty, A. W., Eskandar, E. N., Kostyk, S. K., Thomas, K., Sarkar, A., Siddiqui, M. S., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70039-4 · Cited by 681
van der Kolk, N. M., de Vries, N. M., Kessels, R. P. C., Joosten, H., Zwinderman, A. H., Post, B., & Bloem, B. R. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30285-6 · Cited by 565
Barone, P., Poewe, W., Albrecht, S., Debieuvre, C., Massey, D., Rascol, O., Tolosa, E., & Weintraub, D. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70106-x · Cited by 562
Schenkman, M., Moore, C. G., Kohrt, W. M., Hall, D. A., Delitto, A., Comella, C. L., Josbeno, D. A., Christiansen, C. L., Berman, B. D., Kluger, B. M., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.3517 · Cited by 515
Mirelman, A., Maidan, I., Herman, T., Deutsch, J. E., Giladi, N., & Hausdorff, J. M. (2011) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glq201 · Cited by 418
Randomized Clinical Trial of 3 Types of Physical Exercise for Patients With Parkinson Disease
Shulman, L. M., Katzel, L. I., Ivey, F. M., Sorkin, J. D., Favors, K., Anderson, K. E., Smith, B. A., Reich, S. G., Weiner, W. J., & Macko, R. F. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.646 · Cited by 410
Self-citationWhone, A., Luz, M., Boca, M., Woolley, M., Mooney, L., Dharia, S., Broadfoot, J., Cronin, D., Schroers, C., Barua, N. U., et al. (2019) · Brain · doi:10.1093/brain/awz023 · Cited by 282
Phase I/II randomized trial of aerobic exercise in Parkinson disease in a community setting
Uc, E. Y., Doerschug, K. C., Magnotta, V., Dawson, J. D., Thomsen, T. R., Kline, J. N., Rizzo, M., Newman, S. R., Mehta, S., Grabowski, T. J., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000644 · Cited by 230
Cook, J., Hislop, J., Adewuyi, T., Harrild, K., Altman, D., Ramsay, C., Fraser, C., Buckley, B., Fayers, P., Harvey, I., et al. (2014) · Health Technology Assessment · doi:10.3310/hta18280 · Cited by 194
Phase I trial of hES cell-derived dopaminergic neurons for Parkinson’s disease
Tabar, V., Sarva, H., Lozano, A. M., Fasano, A., Kalia, S. K., Yu, K. K. H., Brennan, C., Ma, Y., Peng, S., Eidelberg, D., et al. (2025) · Nature · doi:10.1038/s41586-025-08845-y · Cited by 181
Christine, C. W., Bankiewicz, K. S., Van Laar, A. D., Richardson, R. M., Ravina, B., Kells, A. P., Boot, B., Martin, A. J., Nutt, J., Thompson, M. E., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25450 · Cited by 167
Nonmotor versus motor symptoms: How much do they matter to health status in Parkinson's disease?
Hinnell, C., Hurt, C. S., Landau, S., Brown, R. G., Samuel, M., & on behalf of the PROMS‐PD Study Group (2012) · Movement Disorders · doi:10.1002/mds.23961 · Cited by 142
Capturing Ambulatory Activity Decline in Parkinson's Disease
Cavanaugh, J. T., Ellis, T. D., Earhart, G. M., Ford, M. P., Foreman, K. B., & Dibble, L. E. (2012) · Journal of Neurologic Physical Therapy · doi:10.1097/npt.0b013e318254ba7a · Cited by 141
Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson’s disease
Niethammer, M., Tang, C. C., LeWitt, P. A., Rezai, A. R., Leehey, M. A., Ojemann, S. G., Flaherty, A. W., Eskandar, E. N., Kostyk, S. K., Sarkar, A., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.90133 · Cited by 124
Frazzitta, G., Bertotti, G., Riboldazzi, G., Turla, M., Uccellini, D., Boveri, N., Guaglio, G., Perini, M., Comi, C., Balbi, P., et al. (2012) · Neurorehabilitation and neural repair · doi:10.1177/1545968311416990 · Cited by 116
Vijiaratnam, N., Girges, C., Auld, G., Chau, M., Maclagan, K., King, A., Skene, S., Chowdhury, K., Hibbert, S., Morris, H., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-047993 · Cited by 84
Mindfulness Training among Individuals with Parkinson’s Disease: Neurobehavioral Effects
Pickut, B., Vanneste, S., Hirsch, M. A., Van Hecke, W., Kerckhofs, E., Mariën, P., Parizel, P. M., Crosiers, D., & Cras, P. (2015) · Parkinson's Disease · doi:10.1155/2015/816404 · Cited by 80
Jitkritsadakul, O., Thanawattano, C., Anan, C., & Bhidayasiri, R. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.08.3246 · Cited by 51
Staging Neurodegenerative Disorders: Structural, Regional, Biomarker, and Functional Progressions
Archer, T., Kostrzewa, R. M., Beninger, R. J., & Palomo, T. (2011) · Neurotoxicity Research · doi:10.1007/s12640-010-9190-2 · Cited by 34
Barbour, P. J., Arroyo, J., High, S., Fichera, L. B., Staska-Pier, M. M., & McMahon, M. K. (2016) · Hospital Practice · doi:10.1080/21548331.2016.1166922 · Cited by 34
Safety of Plasma Infusions in Parkinson's Disease
Parker, J. E., Martinez, A., Deutsch, G. K., Prabhakar, V., Lising, M., Kapphahn, K. I., Anidi, C. M., Neuville, R., Coburn, M., Shah, N., et al. (2020) · Movement Disorders · doi:10.1002/mds.28198 · Cited by 23
Metadata
- Authors
- Shulman, L. M., Gruber-Baldini, A. L., Anderson, K. E., Fishman, P. S., Reich, S. G., & Weiner, W. J.
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2010-01-01
- Volume
- 67
- Issue
- 1
- ISSN
- 0003-9942
- Cited by
- 494
- References
- 4
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review